Basilea Pharmaceutica Articles
Edison analysts' take on Basilea outlook
10 September 2012
Licensing deal for Basilea in sight
13 January 2012
Basilea awarded $130 million in breach of contract arbitration with Johnson & Johnson; updates on isavuconazole program
30 November 2010
Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas
13 September 2010
Showing 1-5 of 5 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
